Lumbar total disk replacement (TDR) has been used in Europe for many years and since 2000 in the United States with the initiation of the Food and Drug Administration investigational device exemption trials. Patients enrolled in those prospective, randomized, controlled trials have now reached 5-year follow-up, the results of which are reported here for the ProDisc-L device. The follow-up rate at 5 years was 81.8% of the 236 patients randomized to either TDR or combined anterior/posterior instrumented fusion. In general, the results were stable from the 2-to 5-year follow-up periods. Both groups remained significantly improved from baseline, with noninferiority of the TDR compared with fusion being maintained. At 5-year follow-up, the range of motion of the levels treated with TDR was 7.7°. The study found that TDR and fusion are both viable treatments for chronic painful degenerative disk disease, with clinical improvements being maintained throughout the 5-year follow-up. Semin Spine Surg 24:25-31 © 2012 Elsevier Inc. All rights reserved.
The single-level investigational and control (360°fusion) cohorts were followed for 24 months, with 98% follow-up rates, and their outcome results, which have been previously reported, 1 served as the basis for FDA approval. These patients have continued annual follow-up per FDA mandate for postmarket surveillance, and their 5-year outcomes are discussed in this chapter.
Patients with symptomatic single-level degenerative disk disease (DDD) who met specific inclusion/exclusion criteria were enrolled in this randomized, controlled, multicenter FDA clinical trial that evaluated total disk replacement (TDR) (ProDisc-L) compared with circumferential fusion. The main inclusion criteria were DDD at 1 vertebral level between L3 and S1, failed conservative treatment for a minimum of 6 months, back and/or leg (radicular) pain, and a minimum Oswestry Disability Index (ODI) score of Ն40% impairment. The average enrolled patient had failed more than 9 months of conservative therapy and had an entry ODI of 63% impairment. Main exclusion criteria were greater than grade I spondylolisthesis, previous lumbar fusion, or clinically relevant facet joint changes.
Seventeen sites and 34 surgeons participated in the study. Patients at each site were randomized in a 2:1 ratio of TDR to circumferential fusion. Separate randomization schedules were generated for each of the 17 sites using a fixed block size of 6, with the randomization performed external to the site after individual patient enrollment. Patients were blinded to randomization until immediately postsurgery. A total of 242 patients were randomized and treated. Six patients were treated off protocol because of intraoperative decision making by their surgeons. In 5 of these patients, the surgeon determined intraoperatively that a 2-level fusion, rather than single-level fusion, was more appropriately indicated and was therefore performed. In the remaining case, a patient with a pars interarticularis defect (exclusion criteria) was erroneously enrolled, randomized to TDR, and treated. Although followed for safety data, these patients were excluded from the efficacy determination.
The surgical procedure has been described in detail previously. 1 The fusion group received anterior-posterior spinal fusion using commercially available femoral ring allograft implanted by a retroperitoneal approach, and a posterolateral fusion with autogenous iliac crest bone graft in combination with pedicle screws. Patients in both cohorts were evaluated preoperatively and postoperatively at 6 weeks and at 3, 6, 12, 18, and 24 months. After completing 24 months of followup, patients were asked to consent to additional follow-up at 36, 48, and 60 months. At each follow-up visit, physical and neurological examinations, radiographs, and patient self-assessments were conducted, including ODI, 2 Short-Form Health Survey (SF-36), pain intensity on a 100-mm visual analogue scale (VAS pain), VAS patient satisfaction, and whether the patient would have the same surgery again. For the purposes of FDA evaluation, a composite success endpoint was defined in the protocol, consisting of 10 success endpoints. The composite measure, termed "statistical success," encompassed the primary effectiveness and safety criteria, summarized in Table 1 . A patient was classified as a statistical success if and only if the patient met all the criteria specified in Table 1 .
Radiographs (anterior-posterior and lateral flexion/extension) were obtained preoperatively and at each follow-up visit, with subjects standing when clinically possible, to ensure the patient's natural anatomical position. Radiographic data were measured and analyzed by an independent radiographic reviewer (Medical Metrics, Inc) who was blinded as to the particular patient history or outcome and had no contact with any investigator.
By design, this was a noninferiority study, with the principal hypothesis being that the randomized ProDisc-L patients would do no worse than the randomized fusion patients at 24 months' evaluation. Data at 2 years and 5 years were compared with baseline within each treatment group using the paired t test. Table 2 summarizes patient enrollment and follow-up. Overall patient follow-up was 97.0% of 236 patients at 2 years and 81.8% of 236 patients at 5 years. Demographics for patients enrolled and treated in the IDE study are shown in Table 3 . This was an extremely well-matched cohort pair, corroborating the efficacy of the randomization paradigm. There were no statistically significant differences between the fusion and TDR patients in any of the demographics, including age, body mass index (BMI), race, smoking status, baseline ODI, or percentage of patients who have had previous surgical treatment.
Results
Intraoperative data were previously reported in detail. 1 The TDR group underwent only an anterior approach, whereas the fusion group underwent both anterior and posterior approaches for the circumferential fusion. The mean intraoperative time was significantly shorter in the TDR group compared with the fusion group (121.7 minutes vs 229.0 minutes, P Ͻ 0.0001). The mean estimated blood loss was lower in the TDR group compared with the control group (203.7 cc vs 466.8 cc, P Ͻ 0.0001). The length of hospital stay was also statistically significantly shorter in the TDR group (3.5 days vs 4.3 days, P Ͻ 0.0001) compared with the control group.
Primary Clinical Outcomes
For FDA evaluation, a composite outcome was determined based on the criteria in Table 1 , where patients had to satisfy all the criteria outlined to be a statistical success. At 2 years, 63.5% of 148 TDR patients and 45.1% of 71 fusion patients achieved overall statistical success, supporting the hypothesis that TDR was noninferior to fusion with 12.5% margin (P Ͻ 0.0001). Although the study was not designed to show a difference, a statistically significant difference in success rates between the TDR and fusion groups at 2 years was found using a 1-sided Fisher exact test (P ϭ 0.0053). At 5 years, 53.7% of 134 of TDR patients and 50.0% of 52 fusion patients were classified as statistical successes. The primary hypothesis of the study that TDR was noninferior to fusion was supported with these 5-year data using 12.5% margin (P ϭ 0.0236). Superiority of TDR over fusion, using this composite outcome success model, was not demonstrated at 5 years (P ϭ 0.7438). Preoperative ODI scores of 63% were similar between fusion and TDR patients (Table 4) . At 2 years, ODI scores improved significantly compared with baseline in both fusion and TDR patients (P Ͻ 0.0001). At 5 years, both treatment groups maintained significant improvements in ODI score compared with baseline (P Ͻ 0.0001).
Mean ODI score improvements for TDR patients were maintained from 2 to 5 years, whereas mean ODI improvements for fusion patients improved in years 3 to 5, and were similar to that of TDR patients at 5 years (P ϭ 0.4552). Most patients in both treatment groups had ODI score improvements of Ն15% at 5 years (76.5% of fusion patients, 78.6% of TDR patients, P ϭ 0.8417) or Ն15 points at 5 years (62.8% of fusion patients, 74.6% of TDR patients, P ϭ 0.1427).
Mean baseline SF-36 physical component scores (PCS) was similar in both TDR and fusion patients (Table 5 ). Both treatment groups experienced improvements in SF-36 PCS compared with baseline at 2 and 5 years of follow-up (P Ͻ 0.0001). At 2 years, TDR patients experienced significantly greater improvements in SF-36 scores compared with that of fusion patients (P ϭ 0.0363); a similar trend was observed at 5 years (P ϭ 0.0986). At 5 years, most patients maintained or improved SF-36 PCS compared with baseline (74.0% of fusion patients, 81.3% of TDR patients, P ϭ 0.3054).
Neurologic success was defined as the maintenance or improvement of patient responses to all neurologic criteria: sensory status, motor status, reflexes, and a straight leg raise test. At 2 years, the TDR group was statistically superior to the control group, with 91.2% success (135/148 patients) compared with 81.4% (57/70 patients), respectively (P ϭ 0.0341). The percentage of patients achieving overall neurologic success at 5 years was similar in TDR patients (111/125 patients, 88.8%) and had increased in fusion patients (43/48 patients, 89.6%). Essentially, there was no significant difference in neurologic success between TDR and fusion patients at 5 years (P ϭ 1.0000).
Radiographic Outcomes
The composite statistical success definition included 6 radiographic outcomes (Table 6 ). The results presented below describe those for patients with available radiographs for the 5-year follow-up visit.
Three TDR patients demonstrated radiographic (but not clinically significant) evidence of device migration at 5 years; in all 3 of these patients, radiographic evidence of migration was first noted at the 3-month follow-up visit. At 5 years, none of the fusion patients with available films had observed device migration. There were 4 fusion patients with observed disk-height decrease (Ͼ3 mm decrease in disk height because of subsidence or graft settling) at the 5-year visit. There were no cases of subsidence (ie, violation of the vertebral endplates Ͼ3 mm) or radiolucency observed in any of the ProDisc-L patients with available radiographs at 5 years. Radiographic films available at 5 years indicated that 2 fusion patients had failed to achieve Ͼ50% trabecular bridging bone, although neither of these patients required a secondary procedure for clinical pseudoarthrosis. Radiographic fusion rates were 97.1% and 95.8% of fusion patients with available films at 2 and 5 years, respectively.
Flexion/extension Range of Motion (ROM) success was defined in the TDR group as restoration to a normal ROM at the implanted level (for L3-L4 and L4-L5 between 6°and 20°; for L5-S1 between 5°and 20°). This ROM success criterion was met by 91.9% of TDR patients at 5 years. Mean flexion/ extension ROM in the TDR group was 7.7°Ϯ 4.7°at 5 years.
Device Success and Index Level Secondary Surgeries Secondary surgeries at the index level occurred in 9 (12%) fusion patients and 13 (8%) TDR patients by the end of the 5-year study, and they impacted the primary endpoint of device success. Device success was defined as absence of any reoperation required to modify or remove implants and no need for supplemental fixation. At 2 years, device success was achieved in 96.3% of 161 TDR patients and 97.3% of 75 fusion patients (P ϭ 1.0000). At 5 years, device success was achieved in 93.2% of 161 TDR patients and 93.3% of 75 fusion patients (cumulative). The 5 TDR patients who were classified as device failures between 3 and 5 years of follow-up underwent supplemental fixation at the index level because of pain, all of whom were addressed posteriorly. One additional patient who received a TDR underwent a secondary surgery at the index level between 3 and 5 years of followup, and was not considered a device failure since the procedure was a hemilaminectomy for nerve decompression.
Between 3 and 5 years of follow-up, 3 fusion patients were considered device failures because they had unresolved pain that required reoperation (6.7% cumulative). Two additional fusion patients had index level surgeries but were not considered device failures because the device or intended treatment was not altered in any way. These 2 fusion patients underwent routine hardware removal for pain; the fusion mass in these patients was confirmed to be solid during the surgery.
Secondary Clinical Outcomes VAS Pain
Both TDR and fusion groups demonstrated significant improvements in VAS pain scores at 2 years and 5 years compared with baseline (P Ͻ 0.0001). Mean percent improvements in VAS pain were similar in TDR and fusion patients at the 2-year and 5-year follow-up visits (Table 7) .
Patient Satisfaction
Patients indicated their satisfaction with treatment on a 100-mm VAS. At 2 years, mean VAS satisfaction was statistically greater in TDR patients vs fusion patients (76.7 Ϯ 29.2 vs 67.3 Ϯ 31.5, respectively; P ϭ 0.0150). At 5 years, TDR patient satisfaction was similar to that at 2 years, whereas fusion patient mean VAS satisfaction increased to a level that was similar to that of TDR patients (TDR: 78.3 Ϯ 27.1, fusion: 78.1 Ϯ 26.7, P ϭ 0.6199). When asked if they would have the same surgery again, 82.5% of TDR patients and 68.0% of fusion patients responded "yes" at 5 years; this was not significantly different between groups (P ϭ 0.1634).
Recreational Activity Status
At baseline, more than half of the enrolled patients were unable to engage in recreational activities. The percentage of TDR, total disk replacement. *P value compares TDR versus fusion using Fisher exact test. †One TDR patient was missing baseline disk height and range of motion measurements because of missing or poor quality radiographs. ‡One fusion patient was missing extension radiographs. 
Complications
At the completion of the study, the number of adverse events reported per patient was similar for the fusion and TDR treatment groups (5.1 and 5.4 per patient, respectively; P ϭ 0.5072). The fusion group had a significantly greater number of reported severe or life-threatening adverse events compared with the TDR group (0.58 and 0.38 per patient, respectively; P ϭ 0.0364).
Complications during the index surgery included 2 control group patients who experienced clinically significant blood loss (Ͼ1500 cc) and 2 additional patients in the control group who experienced dural tears. None of these resulted in clinical sequelae. Postoperatively, retrograde ejaculation was reported in 1 fusion and 2 TDR patients.
There were no infections reported in the TDR group, and 2 posterior wound infections were reported in the control group. Three patients developed deep venous thrombosis after surgery (2 investigational and 1 control) and were successfully treated medically. One TDR patient (0.6%) experienced clinically significant blood loss (Ͼ1500 cc) during revision surgery. At 5 years, 5 patient deaths had occurred (1 fusion and 4 TDR), all due to reasons unrelated to the surgery or implants.
Discussion
The primary hypothesis of this multicenter, prospective, randomized trial was supported at both 2 years and 5 years, allowing the strong conclusion that TDR with ProDisc-L is noninferior to fusion. Although the study was not designed to show superiority, a significant difference favoring TDR was found in statistical success rates at 2 years in several parameters, such as ODI improvement, neurologic success, and radiographic maintenance of disk height.
These TDR and fusion patients who had each failed an average of 9 months of previous conservative care showed improved clinical outcomes over baseline at 2 years and at 5 years of follow-up. Mean clinical outcomes in TDR patients held steady from 2 to 5 years and maintained significant improvement compared with baseline. Fusion patients experienced further improvement in mean clinical outcomes from 2 to 5 years, with mean outcomes reaching levels similar to those observed for TDR patients at 5 years.
The 360°fusion proved to be an excellent control. In the current study, a successful fusion status required strong evidence of fusion, requiring more than 50% trabecular bridging bone or bone mass maturation, increased or maintained bone density at the site, and no visible gaps in the fusion mass, all judged on digitized radiographs by independent radiologists. Using these strict radiographic criteria, the fusion rate in DDD patients who failed conservative treatment was 97.1% at 2 years and 95.8% at 5 years. The fusion rate compared favorably with that reported previously for instrumented fusion in patients undergoing treatment for DDD in prospective randomized studies (73%-95%). [3] [4] [5] [6] It is noteworthy that the patients in the current study received femoral ring allograft and autogenous iliac crest bone graft but no bone morphogenic protein, and that fusion rates in this series of patients were higher than those reported in prospective randomized studies evaluating bone morphogenic protein in single-level DDD patients (eg, 88% reported by Dimar et al, 4 91% reported by Burkus et al 7 ) . These findings further support the quality of surgical treatment provided to the control group.
Summary
A carefully selected population of highly disabled patients with mechanical DDD (failure of conservative treatment for at least 9 months with ODI Ͼ60%) were treated with circumferential spinal fusion or TDR. Not only did patients in both treatment groups experience significant improvements in measurable clinical outcomes at 2 and 5 years, but there were also substantial improvements in the functional status of these patients. Specifically, over 80% of patients in this study experienced improvements in recreational status that was maintained 5 years after index surgery, indicating improvements in their quality of life that were not afforded by months of conservative care. The percentage of patients using narcotics at the 5-year follow-up visit was 39%, less than half the percentage of patients who had used narcotics as part of their failed conservative treatment.
Conclusions
Data from the current study clearly shows that in the appropriately selected patient, spinal surgery is a very effective treatment option for predictably improving patient function while decreasing disability and pain through at least 5 years of follow-up, and is beneficial to the patient using multiple parameters for life quality. The study hypothesis was supported in that TDR surgery with ProDisc-L was demonstrated to be noninferior to fusion at 2 years, and that this benefit was maintained through a minimum of 5 years following surgery. These improvements were dramatic, occurred immediately following surgery, and were maintained through the scope of this follow-up period.
The 5-year results of the ProDisc-L FDA IDE, multicenter, prospective, randomized, control study support either TDR or fusion surgery as a predictable and lasting treatment option to improve pain and function in properly selected patients with mechanical DDD.
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